araag2/HINT huggingface dataset:
Clinical trial NCT00490711 (phase 2, status: completed)
Conditions: epithelial ovarian cancer
ICD codes: H18.523, H18.521, H18.522, H18.529
Drugs: gemcitabine, carboplatin, paclitaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically verified epithelial ovarian cancer

          -  FIGO stage III-IV

          -  Patients with measurable disease. RECIST criteria with GCIG modifications will be used
             for response and for progression assessment.

          -  Lesions serving as measurable disease must have the longest diameter of greater than
             or equal to 20 mm as measured with conventional techniques or greater than or equal to
             10 mm with spiral CT scan. Lesions measured by physical examination must have a
             longest diameter of greater than or equal to 20 mm.

        Exclusion Criteria:

          -  Ovarian tumors with low malignant potential (borderline tumors)

          -  Non-epithelial ovarian or mixed epithelial. non epithelial tumors (e.g. mixed
             Mullerian tumors)

          -  Time between definitive surgery and enrollment into the study is greater than 6 weeks

          -  Patients who have received previous chemotherapy or radiotherapy
Clinical trial NCT00625833 (phase 2, status: terminated)
Conditions: diabetic neuropathies
ICD codes: G60.8
Drugs: placebo, [s,s]-reboxetine
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    study was terminated for futility following the planned interim analysis.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female of any race at least 18 years of age

          -  Diagnosis of painful, distal, symmetrical, sensory-motor polyneuropathy, which is due
             to diabetes, for at least 1 year

          -  Patients at Visit 1 must have a score ≥40 mm on the Pain Visual Analogue Scale

        Exclusion Criteria:

          -  Patients with significant hepatic impairment

          -  Neurological disorders unrelated to diabetic neuropathy that may confuse the
             assessment of neuropathic pain

          -  Any pain or other condition that may confound assessment or self-evaluation of the
             pain due to diabetic neuropathy

          -  Amputations other than toes

          -  A current or recent diagnosis (past 6 months) or episode of major depressive disorder
             and/or uncontrolled depression

          -  History of transient ischemic attack or stroke

          -  Myocardial infarction or unstable angina within the past three months
Clinical trial NCT00631488 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: mk-0893, sitagliptin, metformin, placebo for mk-0893, placebo for sitagliptin, placebo for metformin
SMILES: COC1=CC2=CC=C(C=C2C=C1)C1=CC(=NN1[C@@H](C)C1=CC=C(C=C1)C(=O)NCCC(O)=O)C1=CC(Cl)=CC(Cl)=C1, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CSCC[C@H](N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants who have Type 2 Diabetes Mellitus, with suboptimal glucose control, while
             either not on AHA (antihyperglycemic agent) therapy or on monotherapy or on low-dose
             combination therapy

        Exclusion Criteria:

          -  Participants have a history of Type 1 Diabetes Mellitus

          -  Participants taking insulin or thiazolidinediones (TZDs: peroxisome
             proliferator-activated receptor [PPAR]-gamma agonists)

          -  Participants who have a contraindication to metformin or sitagliptin
Clinical trial NCT01156311 (phase 2, status: completed)
Conditions: relapsing-remitting multiple sclerosis, multiple sclerosis
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0, G35, C81.18
Drugs: dimethyl fumarate
SMILES: [H]\C(=C(\[H])C(=O)OC)C(=O)OC
Eligibility criteria:

        Key Inclusion Criteria:

          -  Must have a confirmed diagnosis of relapsing-remitting multiple sclerosis (RRMS)
             according to McDonald criteria #1-4 (Polman et al, 2005 [Appendix I]), and have a
             prior brain magnetic resonance imaging (MRI) demonstrating lesion (s) consistent with
             multiple sclerosis (MS) from any point in time.

          -  Must have an Expanded Disability Status Scale (EDSS) between 0.0 and 5.0, inclusive.

          -  Must be taking the same dose of a prescribed IFNβ (either Avonex, Betaseron, Rebif) or
             GA for at least 12 months consecutively at the time of enrollment and remain on this
             treatment for the duration of the study. Participants receiving Rebif must be
             prescribed 44 μg by subcutaneous injection three times per week.

        Key Exclusion Criteria:

          -  Primary progressive, secondary progressive, or progressive relapsing MS (as defined by
             Polman et al. 2005).

          -  Other chronic disease of the immune system, malignancies, acute urologic, or pulmonary
             disease.

          -  Pregnant or nursing women.

          -  Participation within 6 months prior to study enrollment in any other drug, biologic,
             or device study.

        NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT00718640 (phase 2, status: terminated)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: dexamethasone, bortezomib
SMILES: C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    study stopped due to lagging enrolment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Participants diagnosed with symptomatic multiple myeloma based on the International
             Myeloma Working Group (IMWG) criteria; greater than or equal to 10 percent plasma
             cells in the bone marrow (or tissue biopsy) detected, monoclonal protein in the serum
             or urine and the, presence of end-organ injury

          -  Participants with measurable disease defined by at least 1 of the following 5
             measurements: a) serum M-protein greater than or equal to 1 gram per deciliter (g/dl),
             b) Urine M Protein greater than or equal to 200 milligram per 24 hour, c) Serum free
             light chain (FLC) assay: Involved FLC level greater than 10 mg per dl (mg/dl) provided
             serum FLC ratio is abnormal, d) Bone marrow plasma cells greater than or equal to 30
             percent

          -  Participants who received at least 1 prior line of chemotherapy for multiple myeloma
             and, is refractory to or has relapsed after the last therapy

          -  Participants with Karnofsky performance status greater than 60 or Eastern Cooperative
             Oncology Group (ECOG) performance status of 0-2

          -  Participants with calculated or measured creatinine clearance of less than or equal to
             30 mililiter per minute (ml/min). During the screening period, 2 measures of
             creatinine clearance at least 7 days apart must be obtained, and both must be less
             than 30 ml/min

        Exclusion Criteria:

          -  Participants who had received bortezomib in previous clinical trial and best response
             was progressive disease or experienced one or more serious events

          -  Participants who received nitorsoureas within 6 weeks, or 2 consecutive weeks of
             intense corticosteroids, or immunotherapy or antibody therapy within 4 weeks before
             enrolment

          -  Participants with history of allergic reaction attributable to compounds containing
             boron or mannitol

          -  Participants with peripheral neuropathy of Grade 2 or greater intensity at the time of
             signing informed consent form

          -  Pregnant or breast-feeding female participants
Clinical trial NCT02005484 (phase 2, status: terminated)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: trastuzumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    study terminated due to slow patient recruitment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients 18-75 years of age;

          -  metastatic or advanced gastric cancer;

          -  disease progression under or after 1 prior platinum-based or 5-fluoropyrimidine-based
             chemotherapy for metastatic disease;

          -  >=4 weeks from last platinum-based or fluoropyrimidine-based chemotherapy;

          -  >=1 measurable lesion;

          -  HER2 overexpression (IHC [2+] or [3+]).

        Exclusion Criteria:

          -  concurrent chemotherapy or immunotherapy;

          -  brain or meningeal metastases;

          -  clinically significant cardiac disease, advanced pulmonary disease or severe dyspnoea;

          -  co-existing malignancies or malignancies diagnosed within last 5 years, except basal
             cell cancer or cervical cancer in situ;

          -  women who are pregnant or breastfeeding.
Clinical trial NCT00562120 (phase 2, status: completed)
Conditions: allergic rhinitis
ICD codes: J30.89, J30.9, J30.2, J30.1, J30.5, J30.81
Drugs: placebo, allegra, allegra-d, pf-03654746
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1, CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1, CCNC(=O)[C@H]1C[C@](F)(C1)C1=CC(F)=C(CN2CCCC2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects 19-55 years with allergic rhinitis requiring treatment within
             the previous 2 years.

          -  Subjects that respond to a ragweed nasal allergen challenge at screening.

        Exclusion Criteria:

          -  History of asthma or FEV1 < 80% predicted.

          -  Significant concomitant disease or medications.

          -  Symptoms of allergic rhinitis within 2 weeks prior to screening.
Clinical trial NCT01038856 (phase 2, status: terminated)
Conditions: polycythemia vera
ICD codes: D45
Drugs: erlotinib
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Reason stopped: 
    the study was terminated by the sponsor
  
Eligibility criteria:

        Inclusion Criteria:

          -  WHO 2008 diagnosis of Polycythemia Vera Hemoglobin > 18.5 g/dl for men (16.5 g/dl for
             women) and presence of JAK2V617F mutation and either bone marrow trilineage
             myeloproliferation or subnormal serum erythropoietin level Patients may be on active
             treatment (phlebotomy, aspirin) ECOG performance status 0,1,2,or 3 Adequate hepatic
             function, adequate renal function

        Exclusion Criteria:

          -  Patient with active malignancy Patients with clinically significant cardiac disease
             within 1 year Opthalmologic or gastrointestinal abnormalities Concurrent cytoreductive
             therapy is not allowed
Clinical trial NCT01405924 (phase 2, status: terminated)
Conditions: nausea, vomiting
ICD codes: R11.0, R11.11, R11.2, R11.10, R11.12, R11.14, R11.11, K91.0, O21.2, O21.8
Drugs: fosaprepitant dimeglumine, 5-ht3 ra, dexamethasone, rescue medication
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Reason stopped: 
    low enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with either breast or gynecological cancer

          -  Receiving either AC-like or CT MEC

          -  Experienced at least 1 episode of vomiting or retching during the first 5 days
             following Cycle 1 of chemotherapy that was thought to be due to chemotherapy. Received
             standard chemotherapy-induced nausea and vomiting (CINV) prophylaxis not containing
             aprepitant or fosaprepitant

          -  No change in chemotherapy at Cycle 2

          -  No change in Cycle 1 antiemetic regimen at Cycle 2

          -  Eastern Cooperative Oncology Group (ECOG) status 0-1

        Exclusion Criteria:

          -  Requires increase in systemic corticosteroid therapy

          -  Used benzodiazepines or opiates in the 48 hours prior to Cycle 2 chemotherapy

          -  Received or will receive radiation therapy to the abdomen or pelvis in the week prior
             to Visit 1 or in Days 1-6 following chemotherapy

          -  Vomited in the 24 hours prior to Treatment Day 1

          -  Pregnant or breast-feeding

          -  Participating in a study with aprepitant or fosaprepitant or has taken an
             investigational drug in the last 4 weeks

          -  Symptomatic central nervous system metastasis

          -  History of other malignancies in the last 2 years
Clinical trial NCT01038037 (phase 2, status: terminated)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: carboplatin, vinorelbine, panitumumab
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Reason stopped: 
    1. very low enrollment rate.

      2. recent studies question the effect of adding panitumumab in this category of patients.

      3. too high toxicity rate
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed metastatic (stage IV) NSCLC

          -  Measurable disease according to RECIST v.1.0 2009

          -  KRAS, BRAF and PI3K wild type in primary tumor or metastatic tissue.

          -  Age ≥18

          -  PS < 2

          -  Adequate organ function

        Haematology:

          -  Neutrophil count ≥1.5x10^9/L

          -  Platelet count ≥100x10^9/L

          -  Leucocyte count > 3,000/mm

        Hepatic function:

          -  Total bilirubin ≤ 1.5 times the upper normal limit (UNL)

          -  Serum transaminases ≤ 2.5xUNL in absence of liver metastases, or ≤ 5xUNL in presence
             of liver metastases

        Renal Function:

          -  Creatinine clearance ≥ 50 mL/min and serum creatinine ≤ 1.5xUNL

        Metabolic function:

          -  Magnesium ≥ lower limit of normal.

          -  Calcium ≥ lower limit of normal.

        Consent to translational research studies

        Written informed consent

        Exclusion Criteria:

          -  Clinically significant cardiovascular disease (including myocardial infarction,
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac
             arrhythmia) ≤ 1 year before enrollment/randomization, active severe infections or
             other concurrent disease.

          -  Known CNS metastasis (pretreatment routine assessment not required)

          -  Prior chemotherapy for metastatic disease

          -  Indication for radiation therapy or prior radiotherapy within 30 days before treatment
             start.

          -  Other malignant diseases within 5 years prior to inclusion in the study, except basal
             cell squamous carcinoma of the skin and cervical carcinoma-in-situ.

          -  Other experimental therapy within 30 days prior to treatment initiation.

          -  History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or
             evidence of interstitial lung disease on baseline chest CT scan.

          -  Patients pregnant or breast feeding, or planning to become pregnant within 6 months
             after the end of treatment.

          -  Patients (male or female) not willing to use highly effective methods of contraception
             (per institutional standard) during treatment and for 6 months (male or female) after
             the end of treatment.
Clinical trial NCT00642811 (phase 2, status: completed)
Conditions: stable coronary artery disease
ICD codes: I25.84, I25.41, I25.42, Z98.61, Q24.5, T46.3X6S, I25.82
Drugs: ticagrelor, clopidogrel, aspirin
SMILES: [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl, N[C@@H](CCCNC(N)=N)C(O)=O, CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with documented stable Coronary Artery Disease (CAD) (stable angina, previous
             MI history, previous history of revascularization)

          -  Females of child bearing potential must have a negative pregnancy test prior to
             receiving study drug and be willing to use a hormonal contraceptive in addition to
             double barrier contraception

        Exclusion Criteria:

          -  History of Acute Coronary Syndromes within 12 months of screening or need for
             revascularization (angioplasty or coronary artery bypass graft (CABG))

          -  Any acute or chronic unstable condition in the past 30 days

          -  Have increased bleeding risk, eg, recent gastrointestinal bleed, uncontrolled high
             blood pressure, low platelet count, recent major trauma

          -  History of intolerance or allergy to aspirin or clopidogrel
Clinical trial NCT00367497 (phase 2, status: terminated)
Conditions: lymphoma, non-hodgkin
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab, etoposide, methylprednisolone, cytarabine, cisplatin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Reason stopped: 
    the stopping rule was applied because of low response rates.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of aggressive non-Hodgkin's lymphoma

          -  Refractory to the first line chemotherapy or relapsed

          -  Expression of CD20 on lymphoma cells

          -  Measurable lesions on imaging studies

        Exclusion Criteria:

          -  Blood cell counts not reaching to 3,000/microliter for white blood cells, 7 g/dl for
             hemoglobin, and 50,000/microliter for platelets without transfusion at the time of
             registration

          -  Circulating lymphoma cells equal to or more than 25,000/microliter

          -  Hepatic dysfunction

          -  Renal insufficiency

          -  Cardiac dysfunction or arrhythmia

          -  Sever infection (bacterial, viral)

          -  CNS involvement

          -  Other malignancies

          -  Pregnancy or breast feeding
Clinical trial NCT00713544 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: azd5672, etanercept, placebo, azd5672, azd5672, azd5672
SMILES: CCN(C1CCN(CC[C@H](C2=CC=C(C=C2)S(C)(=O)=O)C2=CC(F)=CC(F)=C2)CC1)C(=O)CC1=CC=C(C=C1)S(C)(=O)=O, [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCN(C1CCN(CC[C@H](C2=CC=C(C=C2)S(C)(=O)=O)C2=CC(F)=CC(F)=C2)CC1)C(=O)CC1=CC=C(C=C1)S(C)(=O)=O, CCN(C1CCN(CC[C@H](C2=CC=C(C=C2)S(C)(=O)=O)C2=CC(F)=CC(F)=C2)CC1)C(=O)CC1=CC=C(C=C1)S(C)(=O)=O, CCN(C1CCN(CC[C@H](C2=CC=C(C=C2)S(C)(=O)=O)C2=CC(F)=CC(F)=C2)CC1)C(=O)CC1=CC=C(C=C1)S(C)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of RA with active disease defined as: ≥4 swollen joints and ≥6
             tender/painful joints, and either have (blood tests) elevated erythrocyte
             sedimentation rate (ESR) or C-reactive protein (CRP).

          -  At least one of the following: documented history of positive rheumatoid factor (blood
             test), current presence of positive rheumatoid factor (blood test), baseline
             radiographic erosion, presence of serum anti-cyclic citrullinated peptide antibodies
             (bloo

          -  Be receiving either: Oral (tablets) or subcutaneous (injection) methotrexate for at
             least 6 months prior to randomisation.

        Exclusion Criteria:

          -  Any other inflammatory disease in addition to RA that may interfere with the study
             (e.g. polymyalgia rheumatica, giant cell arteritis, reactive arthritis, etc).

          -  Current chronic pain disorders including fibromyalgia and chronic fatigue syndromes.
Clinical trial NCT00504556 (phase 2, status: completed)
Conditions: atrial fibrillation, thromboembolism
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20, O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: edoxaban (du-176b), edoxaban (du-176b), edoxaban (du-176b), edoxaban (du-176b), warfarin
SMILES: CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, S1SSSSSSS1
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female, 18 to 80 years old.

          2. Able to provide written informed consent.

          3. Persistent non-valvular AF supported by abnormal electrocardiogram (ECG)

          4. A congestive heart failure, hypertension, age ≥ 75 years, diabetes, and prior stroke
             (CHADS2) index score of at least 2

        Exclusion Criteria:

          1. Subjects with mitral valve disease or previous valvular heart surgery

          2. Known contraindication to any anticoagulant including vitamin K antagonists such as
             warfarin

          3. Known or suspected hereditary or acquired bleeding or coagulation disorder
Clinical trial NCT00686803 (phase 2, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: pl3994, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have had a diagnosis of essential hypertension for at least 1 year, per
             subject verbal history

          -  Subject must be on a stable dose of at least one, but not more than 3 antihypertensive
             medications for at least 3 months, per subject verbal history.

          -  Subject must have a systolic blood pressure at screening between 100 and 150 mmHg, and
             diastolic blood pressure must not exceed 105 mmHg.

        Exclusion Criteria:

          -  Subject weight greater than 100 kg or less than 50 kg.

          -  Any significant medical condition or abnormal safety laboratory results which, in the
             judgement of the Investigator would place the subject at significant risk.